Vivoryon Therapeutics NV
AEX:VVY
Balance Sheet
Balance Sheet Decomposition
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV
Balance Sheet
Vivoryon Therapeutics NV
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
9
|
8
|
4
|
21
|
21
|
22
|
10
|
4
|
42
|
26
|
14
|
27
|
19
|
9
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
14
|
27
|
13
|
1
|
|
| Cash Equivalents |
9
|
8
|
4
|
21
|
21
|
22
|
10
|
4
|
42
|
26
|
0
|
0
|
6
|
8
|
|
| Short-Term Investments |
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
10
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
2
|
0
|
1
|
0
|
|
| Total Current Assets |
11
|
9
|
6
|
21
|
22
|
22
|
11
|
4
|
45
|
29
|
20
|
31
|
30
|
10
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
6
|
3
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
|
| Intangible Assets |
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
|
| Goodwill |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
|
| Other Assets |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
19
N/A
|
10
-48%
|
6
-37%
|
21
+242%
|
22
+2%
|
22
+2%
|
11
-52%
|
4
-62%
|
46
+1 033%
|
30
-35%
|
25
-18%
|
31
+28%
|
31
-2%
|
11
-63%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
2
|
2
|
0
|
1
|
1
|
1
|
4
|
3
|
3
|
1
|
|
| Accrued Liabilities |
2
|
3
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
3
|
4
|
9
|
5
|
5
|
5
|
1
|
1
|
1
|
1
|
5
|
3
|
3
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
2
|
|
| Total Liabilities |
4
N/A
|
5
+12%
|
11
+128%
|
6
-48%
|
6
+4%
|
6
+4%
|
2
-69%
|
3
+53%
|
3
+13%
|
4
+10%
|
8
+126%
|
5
-39%
|
5
-7%
|
3
-25%
|
|
| Equity | |||||||||||||||
| Common Stock |
23
|
26
|
26
|
7
|
7
|
8
|
8
|
8
|
20
|
20
|
20
|
24
|
26
|
0
|
|
| Retained Earnings |
53
|
72
|
82
|
12
|
26
|
40
|
48
|
55
|
63
|
80
|
92
|
120
|
149
|
169
|
|
| Additional Paid In Capital |
45
|
52
|
52
|
22
|
35
|
48
|
49
|
49
|
86
|
87
|
89
|
123
|
149
|
177
|
|
| Other Equity |
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Total Equity |
15
N/A
|
5
-64%
|
4
N/A
|
16
N/A
|
16
+1%
|
16
+2%
|
9
-46%
|
1
-86%
|
43
+3 369%
|
26
-39%
|
17
-37%
|
27
+60%
|
26
-1%
|
8
-70%
|
|
| Total Liabilities & Equity |
19
N/A
|
10
-48%
|
6
-37%
|
21
+242%
|
22
+2%
|
22
+2%
|
11
-52%
|
4
-62%
|
46
+1 033%
|
30
-35%
|
25
-18%
|
31
+28%
|
31
-2%
|
11
-63%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
7
|
7
|
7
|
7
|
8
|
8
|
8
|
8
|
20
|
20
|
20
|
24
|
26
|
26
|
|